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Objective: The aim of this study is to describe the prevalence of HPV types in invasive cervical cancers in Italy from
1996 to 2008.
Methods: A pooled analysis of the three largest case series typed to date was performed. HPV typing was
performed on paraffin-embedded slices. Molecular analyses were performed in four laboratories. Multivariate
analyses were performed to test the associations between calendar time, age, and geographical area and the
proportion of types 16/18.
Results: Out of 574 cancers, 24 (4.2%) were HPV negative. HPV 16 and 18 were responsible for 74.4% (378/508) and
80.3% (49/61) of the squamous cancers and adenocarcinomas, respectively. Other frequent types were 31 (9.5%),
45 (6.4%), and 58 (3.3%) for squamous cancers and 45 (13.3%), 31, 35, and 58 (5.0%) for adenocarcinomas. The
proportion of HPV 16 and/or 18 decreased with age (p-value for trend <0.03), while it increased in cancers
diagnosed in more recent years (p-value for trend < 0.005).
Conclusions: The impact of HPV 16/18 vaccine on cervical cancer will be greater for early onset cancers. In
vaccinated women, screening could be started at an older age without reducing protection.Background
Cervical cancer is still the second leading cancer in
women worldwide, with 585,278 new cases estimated in
2010. More than 80% of these cases occurred in low-
medium income countries [1,2]. In Italy, the incidence
has been decreasing over the last few decades and now
only 2800 new cases per year (8.2/100000 EUR STD) are
estimated [3].
It has been demonstrated that HPV infection is a
necessary cause for cervical cancer [4]. In particular,
12 high-risk types [5] cause about 90% of all cases.
The prevalence of HPV types infecting the lower geni-
tal tract in the healthy population shows geographical
variations [6]. Instead, the prevalence of HPV types in
cancer is much more stable across geographic areas: type
16 is always the most represented, followed by 18, 45, 31,
and 33 [7,8].* Correspondence: paolo.giorgirossi@ausl.re.it
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distribution, and reproduction in any mediumNevertheless, some differences among continents have
been consistently observed: In Africa and Eastern Asia,
the proportion of cancers due to HPV types 16 and 18
is slightly lower than in Western Europe and North
America [7,8]. Furthermore, early onset cancers are more
frequently linked to HPV 16, 18, and 45 [7,9].
Many hypotheses have been formulated to explain
these differences. The one most commonly accepted to
explain the higher proportion of type 16 in early onset
cancers is that this type has a greater potential to trans-
form the cell compared to other high-risk HPV types and
consequently there is a higher probability of progression
from infection to cancer in a relatively short time. There
is evidence from prospective cohort studies of shorter
time to progression from HPV16 infection to high-grade
Cervical Intraepithelia Neoplasia (CIN 3) [10-12]. How-
ever, this cannot be demonstrated for cervical cancer since
CIN 3 and even CIN 2 must be treated once detected.
Data from cohort studies on time to progression for
types 18 and 45 are less consistent [10,11] because these
types are quite uncommon in the general populationntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in vitro transformation data as well as by epidemiological
case–control and cross-sectional studies.
The prevalence of cytological screening uptake in
the population strongly influences the epidemiology of
cervical cancer. In highly screened populations, Pap test’s
greater efficacy in detecting squamous precancerous
lesions than glandular lesions leads to marked reduction
in the incidence in the former [13,14] and smaller re-
duction in the latter [15-17]. Furthermore, cytological
screening shows higher efficacy in decreasing the inci-
dence in women 30 years and older [18]. Consequently,
the ratio between early onset and late onset and be-
tween squamous cancers and adenocarcinomas changes
in screened population.
Objective
The aim of this work is to describe the prevalence of
HPV types in Italian invasive cervical cancers from 1996
to 2008. The study is based on the pooling of three cases
large series [9,19,20].
In particular, we describe the associations between
ca lendar time, age, and geographical area and the pro-
portion of vaccine-targeted types (16 and 18) and early
onset types (types 16/18/45).
Methods
Study population, selection cases
Histologically confirmed cervical cancer diagnoses from
three large series were included in the study. All three
studies performed ad hoc morphological and molecular
analyses on archival paraffin-embedded invasive cervical
cancer (ICC) specimens.
Central and Southern Italy Study [9]: 193 cases from
eight centers (S. Giovanni Hospital in Rome and Belcolle
Hospital in Viterbo, in Lazio; National Cancer Institute
Fondazione Pascale in Naples, Campania; Atri, Abruzzo;
Catania, Sicily; Cagliari, Sardinia; ISPO and S. Maria
Annunziata Hospital in Florence, Tuscany) diagnosed
between 1999 and 2008.
Rome Study [19]: 134 cases between 2001 and 2006,
mostly in residents in central Italy, identified at and
retrieved from the Regina Elena Cancer Institute in Rome.
Milan Study [20]: 268 cases from all over the country -
Milan and surrounding area (n = 57, 21.3%), northern
Italy (n = 81, 30.2%), central Italy (n = 64, 23.9%), and
southern Italy (n = 66, 24.6%) - referred to the European
Institute of Oncology between 1996 and 2006.
Pathology and laboratory procedure
Paraffin block selection and microtome sectioning, per-
formed under strict conditions to avoid potential con-
tamination, employed a sandwich technique to obtain
5 or 10-μm tissue section from each paraffin block. Firstand last microtome sections were stained for histo-
pathological evaluation, while the internal sections were
processed for DNA extraction. In one centre (Naples),
morphologic check showed that the mean percentage
of tumor cell staining was 64% (range: 5-100%), with a
relevant proportion of sample slices containing a limited
quantity of neoplastic tissue within a healthy tissue
context.
No central histologic review was planned for this
study.
DNA extraction and HPV typing
Molecular analyses were performed in four centers: the
Milan Study sent specimens to the International Agency
for Research on Cancer (IARC, Lyon, France) [20], the
Rome Study to the Catalan Institute of Oncology-ICO
Survey [19], and the Central and Southern Italy Study to
the laboratory at ISPO in Florence and to the Pascale
National Cancer Institute in Naples [9].
For each sample, DNA concentration was evaluated by
spectrophotometry and expressed in ng/μL.
HPV genotyping was done using different PCR-based
strategies in a well-defined algorithm.
The Central and Southern Italy study
A PCR assay based on GP5+/GP6+ primers was used
(Consensus High Risk HPV Genotyping kit, Digene,
Qiagen). All samples and controls were subjected to the
reverse line blot (RLB) for detection of 12 high-risk HPV
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59),
1 probably carcinogenic HPV type (68), and 5 possibly
carcinogenic HPV types (26, 53, 66, 73, and 82) [9]. To
amplify negative samples and to overcome any false nega-
tives due to inhibitors commonly present in formalin-
fixed samples or due to low copy number of HPV DNA,
a sequence of steps was carried out [9].
The Rome study
For genotyping HPV DNA, 10 μl of the PCR amplimers
of the HPV DNA-positive samples, as identified by DEIA,
were analyzed by Line Probe Assay-LiPA25 version 1
(Labo Biomedical Products, Rijswijk ,The Netherlands),
which can detect 25 different high-risk and low-risk HPV
types (6, 11, 16, 18, 31, 33, 34, 35, 39,40, 42, 43, 44, 45,
51, 52, 53, 54, 56, 58, 59, 66, 68, 70,74) [19].
The Milan study
Multiplex PCR was performed using the Qiagen Multi-
plex PCR Kit according to the manufacturer’s instruc-
tions, with a mixture containing 19 pairs of HPV-type
specific primers (type 16, 18, 26, 31, 33, 39, 45, 51, 52, 53,
56, 58, 59, 66, 68, 70, 73, 82) following the procedure
described by Gheit et al. [21]. To increase the sensitivity
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E7 was modified as described by Cazzaniga et al. [22].
Statistical analysis
Our tables show the type distribution found in squamous and
cervical cancers. We also present the proportion of types 16
and 18 or 16, 18, and 45 by age, calendar time at diagnosis,
and geographic area. Proportions with relative 95% confidence
intervals were computed. Multivariate models were con-
structed to identify determinants of the proportion of vaccine-
covered types (16 and 18) and early onset types (16, 18 and
45). All the analyses were performed using STATA 11.0.
Results
After histological evaluation, 595 ICC specimens from
the original studies were included. Of these, 4 cases from
the Rome Study and 17 from the Milan Study were
excluded from the present study because the information
about typing was missing. Thus, 574 cases were available
for the analyses.Table 1 HPV types by histotype
Squamous cell carcinoma A
ALL 508
N %























not typed 4 0.8
*including five other minor histotypes; three cases with HVP type 18 and two casesThe age range of the women included in this study
was 23–85 years (mean age 52.4 years).
Squamous cell carcinoma was the most represented
histotype (508 cases: 88.5%), followed by adenocarcinoma
(55 cases: 9.6%), then adenosquamous cell carcinoma
(6 cases: 1.0%), and other minor histotypes (5 cases:
0.9%). For all the following analyses, adenosquamous cell
carcinomas were grouped with adenocarcinomas.
Adenocarcinoma was not associated with age at diag-
nosis (p = 0.57), but a strong time trend, with increasing
proportion of adenocarcinomas in the recent years, was
observed (p-value for trend <0.002).
Twenty-four (4.2%) cases were HPV DNA-negative.
Among the HPV-positive cases, 74 (13.4%) were mul-
tiple infections, and 7 cases were non-typed.
HPV 16 was the most frequent type detected,
alone or in coinfection with other types: 69.3% and
58.3% in squamous and adenocarcinomas, respectively




N % N %
1 1.6 24 4.2
0 0.0 2 0.4
35 58.3 373 67.8
14 23.3 59 10.7
3 5.0 49 8.9
0 0.0 14 2.5
3 5.0 12 2.2
0 0.0 5 0.9
0 0.0 2 0.4
8 13.3 39 7.1
0 0.0 7 1.3
0 0.0 9 1.6
1 1.7 4 0.7
1 1.7 6 1.1
3 5.0 19 3.5
1 1.7 6 1.1
0 0.0 5 0.9
0 0.0 1 0.2
0 0.0 3 0.5
0 0.0 4 0.7
0 0.0 9 1.6
0 0.0 1 0.2
3 5.0 7 1.3
with HVP type 16.
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nomas (23.3%), and third in squamous (8.7%; p-value =
0.0003). The cumulative proportion of HPV 16 and/or
HPV 18 was slightly higher in adenocarcinomas than in
squamous cell carcinomas, though not significantly
(81.8% vs 74.4%, p-value = 0.2). HPV 45 was also more
frequent in adenocarcinomas than in squamous (13.3%
vs 6.4%, p-value = 0.04), while HPV 31 was more fre-
quent in squamous cell carcinomas, though not signifi-
cantly so (9.5% vs 5.0%). The fifth most frequent type
was HPV 58 (3.3% and 5.0% in squamous and adenocar-
cinomas, respectively). HPV 33 ranked sixth (2.9% in
squamous and null in adenocarcinomas), and HPV
35 ranked seventh (1.9% and 5% in squamous and adeno-
carcinomas, respectively).
There was no significant difference in the geographical
distribution of HPV 16 and 18, whereas we observed a
significant (p-value = 0.03), higher proportion of HPV 31
in northern Italy (13.1%) than in central and southern
Italy (7.5% and 6.8%, respectively) (Table 2).Table 2 HPV types by Italian geographical area
north centre south
ALL 154 193 205
N % N % N
HPV negative 1 0.6 6 3.1 14
HPV types
6 0 0.0 1 0.5 1
16 100 65.4 127 67.9 134
18 19 12.4 18 9.6 22
31 20 13.1 14 7.5 13
33 6 3.9 3 1.6 4
35 4 2.6 2 1.1 5
39 2 1.3 2 1.1 1
42 0 0.0 1 0.5 1
45 9 5.9 16 8.6 12
51 3 2.0 1 0.5 2
52 5 3.3 3 1.6 1
53 2 1.3 2 1.1 0
56 2 1.3 3 1.6 1
58 5 3.3 8 4.3 6
59 3 2.0 0 0.0 3
66 1 0.7 2 1.1 2
67 0 0.0 1 0.5 0
68 1 0.7 0 0.0 2
70 2 1.3 0 0.0 1
73 5 3.3 2 1.1 2
82 1 0.7 0 0.0 0
not typed 0 0.0 3 1.6 4There was a significant decreasing trend of HPV 16
and 18 in proportion with age, dropping from 94% to
about 75% after the age of 35 (p-value = 0.03). The trend
was even stronger when we included HPV 45 (p-value =
0.005) (Table 3).
There was also a significant trend in the proportion of
types 16 and 18 with calendar time, with a higher pro-
portion in the more recent years (p-value = 0.005)
(Table 4), with no heterogeneity among centres.
The multivariate model shows that the effects of age
and calendar time are independent and that they are not
due to any bias in center recruitment and laboratory
techniques adopted for typing. The same results are
obtained if we limit the analyses to squamous cell cancers
(Table 5); stratified analyses for adenocarcinoma were
not performed due to small numbers.
Discussion
These three large Italian case series confirm some
previously published results [7,8]. The proportion ofand islands abroad & missing Total
22 574
% N % N %
6.8 3 13.6 24 4.2
0.5 0 0.0 2 0.4
70.2 12 63.2 373 67.8
11.5 1 5.3 60 10.9
6.8 2 10.5 49 8.9
2.1 1 5.3 14 2.5
2.6 1 5.3 12 2.2
0.5 0 0.0 5 0.9
0.5 0 0.0 2 0.4
6.3 2 10.5 39 7.1
1.0 1 5.3 7 1.3
0.5 0 0.0 9 1.6
0.0 0 0.0 4 0.7
0.5 0 0.0 6 1.1
3.1 0 0.0 19 3.5
1.6 0 0.0 6 1.1
1.0 0 0.0 5 0.9
0.0 0 0.0 1 0.2
1.0 0 0.0 3 0.5
0.5 1 5.3 4 0.7
1.0 0 0.0 9 1.6
0.0 0 0.0 1 0.2
2.1 0 0.0 7 1.3
Table 3 HPV types 16/18 and HPV types 16/18/45 by histotype, study and age
<=24 25-34 35-44 45-54 55-64 65+ All ages
Histological type
Squamous cell carcinoma 16/18 (n) 1 40 108 85 61 69 364
% 100,0 93,0 76,1 72,6 72,6 75,0 76,0
16/18/45 (n) 1 41 118 94 64 72 390
% 100 95,3 83,1 80,3 76,2 78,3 81,4
Any type (n) 1 43 142 117 84 92 479
Adeno- and Adenosquamous cell carcinoma 16/18 (n) 0 5 15 5 10 8 43
% 0 100 93,8 55,6 83,3 61,5 76,8
16/18/45 (n) 1 5 15 6 11 11 49
% 100 100 93,8 66,7 91,7 84,6 87,5
Any type (n) 1 5 16 9 12 13 56
Study
Milan Study 16/18 (n) 0 25 65 44 38 15 187
% - 89,3 75,6 71,0 73,1 71,4 75,1
16/18/45 (n) 0 26 70 49 38 16 199
% - 92,9 81,4 79,0 73,1 76,2 79,9
Any type (n) 0 28 86 62 52 21 249
Rome Study 16/18 (n) 1 9 25 14 16 15 80
% 100,0 100,0 69,4 60,9 84,2 62,5 71,4
16/18/45 (n) 1 9 28 17 16 15 86
% 100,0 100,0 77,8 73,9 84,2 62,5 76,8
Any type (n) 1 9 36 23 19 24 112
Central and Southern Italy Study 16/18 (n) 0 11 33 32 17 47 140
% 0,0 100,0 91,7 78,0 68,0 78,3 80,5
16/18/45 (n) 1 11 35 34 21 52 154
% 100,0 100,0 97,2 82,9 84,0 86,7 88,5
Any type (n) 1 11 36 41 25 60 174
Total 16/18 (n) 2 46 124 91 71 78 412
% 66,7 93,9 78,0 71,7 74,0 73,6 76,3
16/18/45 (n) 3 47 134 101 75 84 444
% 100 95,9 84,3 79,5 78,1 79,2 82,2
Any type (n) 3 49 159 127 96 106 540
*including five other minor histotypes; three cases with HPV type 18 and two cases with HPV type 16; one case in each age class except 55–64 years old.
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with that recently published by IARC (92.5%), meaning
that the average quality of specimens and laboratory pro-
cedures was good.
Again, in line with de Sanjose’s study, HPV 16 and
18 were detected in about 77% of cervical cancers [7].
This proportion is higher than that observed in prein-
vasive lesions (CIN2 and CIN3) in the same popula-
tions [9,23], which is consistent with findings in almost
all the previous studies [24,25]. The proportions of
HPV 18 and 45 are higher in adenocarcinomas than in
squamous cancers, as previously reported in larger
studies [7,8,26].It is interesting that HPV 33 did not rank in the top
five, in contrast with the worldwide distribution. Other
studies have already reported higher prevalence of HPV
31 than 33 in southern Europe [8].
In our series, more than 1 out of 9 cases were adeno-
carcinomas, which is typical of high-moderate screening
coverage [27], but the proportion of adenocarcinomas
showed an increasing time trend during the study period,
as expected, since Pap test coverage increased over the
same period [28].
The main objective of this paper was to describe
changes in the proportion of vaccine-covered HPV types
16 and 18 and in early onset HPV types 16, 18, and 45,
Table 4 HPV types 16/18 and HPV types 16/18/45 by histotype, study and year of diagnosis
1999° 2000 2001 2002 2003 2004 2005 2006 2007 2008 All
years
Histological type
Squamous cell carcinoma 16/18 (n) 16 23 30 34 56 60 62 62 13 9 365
% 64,0 74,2 73,2 66,7 73,7 76,9 75,6 89,9 81,3 81,8 75,9
16/18/45 (n) 18 24 30 37 64 65 68 63 14 9 392
% 72,0 77,4 73,2 72,5 84,2 83,3 82,9 91,3 87,5 81,8 81,5
Any type (n) 26 31 41 51 76 78 82 69 16 11 481
Adeno- and Adeno-squamous
cell carcinoma
16/18 (n) 0 2 1 3 6 5 9 10 7 0 43
% - 50,0 50,0 75,0 85,7 100,0 75 83,3 70 - 76,8
16/18/45 (n) 0 2 2 4 6 5 11 11 8 0 49
% - 50,0 100,0 100,0 85,7 100,0 91,7 91,7 80 - 87,5
Any type (n) 0 4 2 4 7 5 12 12 10 0 56
Study
Milan Study 16/18 (n) 11 20 19 22 28 24 33 29 1 0 187
% 61,1 71,4 70,4 71,0 68,3 85,7 82,5 85,3 100,0 - 75,1
16/18/45 (n) 12 21 19 23 32 24 36 31 1 0 199
% 66,7 75,0 70,4 74,2 78,0 85,7 90,0 91,2 100,0 - 79,9
Any type (n) 19 28 27 31 41 28 40 34 1 0 249
Rome Study 16/18 (n) 0 0 7 8 16 22 16 11 0 0 80
% - - 100,0 50,0 76,2 71,0 66,7 84,6 - - 71,4
16/18/45 (n) 0 0 7 10 17 24 17 11 0 0 86
% - - 100,0 62,5 81,0 77,4 70,8 84,6 - - 76,8
Any type (n) 0 0 7 16 21 31 24 13 0 0 112
Central and Southern
Italy Study
16/18 (n) 5 5 5 7 18 19 22 32 19 9 134
% 71,4 71,4 55,6 87,5 85,7 79,2 73,3 94,1 76,0 81,8 76,1
16/18/45 (n) 6 5 6 8 21 22 26 32 21 9 156
% 85,7 71,4 66,7 100,0 100,0 91,7 86,7 94,1 84,0 81,8 88,6
Any type (n) 7 7 9 8 21 24 30 34 25 11 176
Total Squamous cell carcinoma 16/18 (n) 16 25 31 37 65 66 72 72 20 9 413
% 64,0 74,2 73,2 66,7 73,7 76,9 75,6 89,9 81,3 81,8 75,9
16/18/45 (n) 18 26 32 41 73 71 80 74 22 9 446
% 72,0 77,4 73,2 72,5 84,2 83,3 82,9 91,3 87,5 81,8 81,5
Any type (n) 26 35 43 55 86 84 95 81 26 11 542
*including five other minor histotypes; three cases with HPV type 18 and two cases with HPV type 16; Three cases diagnosed in 2003, one in 2004 and one in
2005.
°Including one case occurred in 1998.
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time.
Only few differences among geographic areas emerged
and, even when statistically significant, they may have
been due to chance, given the enormous number of sta-
tistical tests that can be performed comparing these
distributions.
The most remarkable results in our analyses were the
trends in HPV 16, 18, and 45 with age and calendar
time. The multivariate analysis clearly shows that thetwo trends are independent and not due to reciprocal
confounding, to the increase in adenocarcinomas pro-
portion in recent years, or to different PCR techniques
adopted for typing in the three studies.
The relation with age was expected since these are
known to be early onset types [7,9,20,29], particularly
HPV16, which showed a higher probability of progres-
sion [10,11]. In fact, if we assume a multi-step model in
cancer progression, a higher probability of progression
will produce a higher proportion of cases in younger
Table 5 Multivariate models
Any Histotype
HPV types 16/18 OR* 95% CI P-value
age 0.98 0.97 1.00 0.030
year 1.16 1.05 1.29 0.005
§including histotype in the covariates has no effect (p-value = 0.9)
HPV types 16/18/45 OR* 95% CI P-value
age 0.98 0.96 0.99 0.005
year 1.17 1.04 1.31 0.008
§including histotype in the covariates has no effect (p-value = 0.7)
Squamous cell carcinoma
HPV types 16/18 OR* 95% CI P-value
age 0.99 0.97 1.00 0.076
year 1.16 1.04 1.30 0.008
HPV types 16/18/45 OR* 95% CI P-value
age 0.98 0.96 0.99 0.006
year 1.17 1.03 1.32 0.012
*Adjusted by study
Determinants of the proportion of the vaccine-covered types (16 and 18) and
early onset types (16, 18 and 45) for any histotype and squamous cell
carcinoma.
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has only recently begun. Differently from the large study
by de Sanjose and collaborators [7], our trend was due
to an excess of HPV 16, 18 and 45 HPV-related squa-
mous cancer in women below age 35, but we did not
have enough statistical power to accurately describe the
shape of the curve.
On the contrary, the association with calendar time
was not observed in other large series [30,31] and we
must therefore assume it is a context-specific finding. It
must be noted that the screening coverage in Italy has
increased over the last decade, from 50% in 1994 to 73%
in 2004. The increase in screening coverage has the
immediate effect of decreasing the overall incidence
of cervical cancer, as illustrated by the dramatic de-
crease in incidence in Italy, from 9.2/100.000 in 1996 to
7.7/100.000 in 2005 [28]. However, Pap-test preventive
efficacy is not the same for all the cancers. Indeed, it is
well known that the efficacy of screening is stronger for
squamous cancers than for adenocarcinomas [15-17],
and it has recently been demonstrated that the efficacy is
very low for early onset cancers [18]. In line with these
observations, screening might be less effective for those
cancers caused by HPV 16, 18 and 45, virus types known
to be associated with early onset. Consequently, in a
highly screened population, the few cases occurring are
in part those occurring in the under-screened or not co-
vered minority. Further, a relevant proportion is also
made up of the few cases occurring during the intervalbetween two screening episodes. The cases escaping the
Pap-test control, according to this hypothesis, are more
likely to be linked to HPV 16, 18, or 45.
The possibility of a more rapid progression associated
with HPV 16 and its variants is supported by the Guana-
caste Cohort Study, a 7-year nested case–control study
conducted on 10,049 women [32]. The study showed
that HPV 16 viruses, particularly non-European HPV 16
variants (mainly Asian American, AA), are significantly
associated with higher risk of developing invasive cer-
vical cancer [OR, 6.3 (95% CI, 1.6–24.6)]. Similar data
have also been reported for HPV 16 AA variants in the
Italian population, with a relative risk of 24.5 of develop-
ing invasive cervical cancer [33].
Another hypothesis is that HPV 16/18/45-related
cancer precursors occur at a younger age, are far superior
in number in comparison with other high-risk HPV-
related cancer precursors, are not easily detected by
cytology screening, and the transit time from precursor
to cancer is not necessarily quicker. Recent population-
based studies have shown that by using very sensitive
screening tests such as HPV DNA testing, the number of
precancerous lesions missed by cytology proves to be
considerable [34]. This lack of cytology screening sensi-
tivity is particularly evident in the younger age groups,
where HPV testing may detect high-grade CINs more
frequently than cytology [34]. It is already known that
high-grade CINs occurring at a young age are mostly
related to HPV 16/18 [9,29]; the trend in distribution of
HPV genotypes in invasive cancers in different calendar
years observed in the present study may therefore be the
result of the faster and more frequent formation of high-
grade CINs in young girls and the inability of cytology
screening to detect most of these lesions, typically related
to HPV 16/18/45. The large number of high-grade CINs
left in situ could then generate invasive lesions between
two screening intervals more frequently than would the
other high-risk genotypes, whose ability to persist and
generate CIN3 lesions is less efficient than HPV16 and,
albeit less markedly, than 18.
Both these hypotheses consider the three HPV types
related to early onset cancers as a unique group, but the
evidence available about speed of progression from infec-
tion to CIN3 and cancer and about screening sensitivity
are different for HPV 16 and HPV 18, and are almost
absent for HPV 45.
In conclusion, the proportion of HPV 16 and 18 types
may be higher in highly screened populations because
these types more frequently escape Pap test control.
Consequently, the dramatic decrease in cancer incidence
after screening introduction may be slightly less relevant
for HPV 16- and 18-related cancers. Unfortunately, the
effectiveness of Pap test as prevention cannot easily be
increased by shortening screening intervals; a large body
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to 1 has a small effect on cancer incidence and a strong
effect on the number of screening-induced treatments
[35,36]. On the contrary, by shifting to HPV as primary
screening test, we can imagine a protocol that increases
protection and decreases over-treatment, adopts longer
intervals for HPV-negative women, and modulates the
follow up for HPV-positive women according to the
genotype.
Limits
As the present study has several limits, we can only con-
firm previously observed data or formulate hypotheses
to be confirmed in other studies.
The first limitation is that we did not perform a central
pathology review, even if all the cases were specifically
reviewed for the original study in each center [9,19,20].
As typing was performed on archival paraffin-embedded
samples, some trends could be due to reduced analytical
accuracy of typing methods on older samples, but this is
not very likely to change the proportion of types.
Our archives do not report some of the information
that might have been crucial to testing our hypothesis.
In particular, we do not know if the cases had had a pre-
vious negative Pap test. Furthermore, we do not know
the stage at diagnosis. It could be extremely interesting
to identify the micro-invasive cancers (FIGO IA1), since
these cancers are virtually all asymptomatic and are thus
mostly screen-detected [37].
Finally, our series do not come from population-based
registries and thus may not represent the universe of can-
cers in Italy. Furthermore, in some of the areas with
higher screening coverage, i.e., northern Italy and Rome,
the participating centers are not reference centre for
screening programs, while in the areas with lower screen-
ing coverage, i.e. southern Italy, they are. It is likely that
the proportion of screening-detected cancers in our
archives does not represent the proportion in the cancer
population in each geographic area. This may explain
why we did not observe an effect of the geographic area
on the proportion of HPV 16, 18, or 45, despite the broad
differences in screening coverage among the areas.
Conclusions
The impact of HPV 16/18 vaccine on cervical cancer will
be proportionally more relevant for early onset cancers.
Considering the very low overall risk in women under
age 35 and that the proportion of vaccine-targeted can-
cers is over 90% in that age group, it may be necessary
to postpone starting age for screening in vaccinated
cohorts in order to reduce the risk of over-treatment
and to contain costs.
Furthermore, we suggest that screening is less effective
in preventing the incidence of HPV 16 and 18 invasivecancers, given their shorter sojourn time in the precan-
cerous stages. If this is true, then the screening interval
in vaccinated women should take into account the
longer sojourn time of CIN2 and CIN3 lesions due to
non-16/18 HPV types.Ethical Approval
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